Booty Matthew G, Chae Jae Jin, Masters Seth L, Remmers Elaine F, Barham Beverly, Le Julie M, Barron Karyl S, Holland Steve M, Kastner Daniel L, Aksentijevich Ivona
Genetics and Genomics Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland 20892-1820, USA.
Arthritis Rheum. 2009 Jun;60(6):1851-61. doi: 10.1002/art.24569.
Familial Mediterranean fever (FMF) has traditionally been considered an autosomal-recessive disease; however, it has been observed that a substantial number of patients with clinical FMF possess only 1 demonstrable MEFV mutation. The purpose of this study was to perform an extensive search for a second MEFV mutation in 46 patients diagnosed clinically as having FMF and carrying only 1 high-penetrance FMF mutation.
MEFV and other candidate genes were sequenced by standard capillary electrophoresis. In 10 patients, the entire 15-kb MEFV genomic region was resequenced using hybridization-based chip technology. MEFV gene expression levels were determined by quantitative reverse transcription-polymerase chain reaction. Pyrin protein levels were examined by Western blotting.
A second MEFV mutation was not identified in any of the patients who were screened. Haplotype analysis did not identify a common haplotype that might be associated with the transmission of a second FMF allele. Western blots did not demonstrate a significant difference in pyrin levels between patients with a single mutation and those with a double mutation; however, FMF patients of both types showed higher protein expression as compared with controls and with non-FMF patients with active inflammation. Screening of genes encoding pyrin-interacting proteins identified rare mutations in a small number of patients, suggesting the possibility of digenic inheritance.
Our data underscore the existence of a significant subset of FMF patients who are carriers of only 1 MEFV mutation and demonstrate that complete MEFV sequencing is not likely to yield a second mutation. Screening for the set of the most common mutations and detection of a single mutation appears to be sufficient in the presence of clinical symptoms for the diagnosis of FMF and the initiation of a trial of colchicine.
家族性地中海热(FMF)传统上被认为是一种常染色体隐性疾病;然而,据观察,大量临床诊断为FMF的患者仅携带1个可证实的MEFV突变。本研究的目的是在46例临床诊断为FMF且仅携带1个高穿透性FMF突变的患者中广泛寻找第二个MEFV突变。
通过标准毛细管电泳对MEFV和其他候选基因进行测序。在10例患者中,使用基于杂交的芯片技术对整个15kb的MEFV基因组区域进行重测序。通过定量逆转录-聚合酶链反应测定MEFV基因表达水平。通过蛋白质免疫印迹法检测吡啉蛋白水平。
在所有筛查的患者中均未鉴定出第二个MEFV突变。单倍型分析未发现可能与第二个FMF等位基因传递相关的常见单倍型。蛋白质免疫印迹法未显示单突变患者和双突变患者之间吡啉水平存在显著差异;然而,与对照组以及患有活动性炎症的非FMF患者相比,这两种类型的FMF患者均表现出更高的蛋白质表达。对编码与吡啉相互作用蛋白的基因进行筛查,在少数患者中发现了罕见突变,提示存在双基因遗传的可能性。
我们的数据强调了存在相当一部分仅携带1个MEFV突变的FMF患者,并表明对MEFV进行完整测序不太可能发现第二个突变。在存在临床症状的情况下,筛查最常见的一组突变并检测到单个突变似乎足以诊断FMF并启动秋水仙碱试验。